Title |
NKG2D Ligands in Tumor Immunity: Two Sides of a Coin
|
---|---|
Published in |
Frontiers in immunology, March 2015
|
DOI | 10.3389/fimmu.2015.00097 |
Pubmed ID | |
Authors |
Jinyu Zhang, Fahmin Basher, Jennifer D. Wu |
Abstract |
The activating/co-stimulatory receptor NKG2D (natural-killer group 2, member D) is expressed on the surface of all human NK, NKT, CD8(+) T, and subsets of γδ(+) T cells. The significance of NKG2D function in tumor immunity has been well demonstrated in experimental animal models. However, the role of human NKG2D ligands in regulating tumor immunity and cancer prognosis had been controversial in the literature. In this review, we summarize the latest advancement, discuss the controversies, and present evidence that membrane-bound and soluble NKG2D ligands oppositely regulate tumor immunity. We also discuss new perspectives of targeting NKG2D ligands for cancer immunotherapy. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 33% |
Switzerland | 1 | 33% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | <1% |
United States | 1 | <1% |
Denmark | 1 | <1% |
Unknown | 211 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 49 | 23% |
Researcher | 30 | 14% |
Student > Master | 27 | 13% |
Student > Bachelor | 24 | 11% |
Student > Doctoral Student | 17 | 8% |
Other | 30 | 14% |
Unknown | 37 | 17% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 45 | 21% |
Immunology and Microbiology | 44 | 21% |
Biochemistry, Genetics and Molecular Biology | 32 | 15% |
Medicine and Dentistry | 30 | 14% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 2% |
Other | 13 | 6% |
Unknown | 46 | 21% |